• Altamira Therapeutics Ltd (NASDAQ: CYTO) announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis.

• The HDM challenge trial demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls and good tolerability and safety.

• Bentrio is a drug-free nasal spray intended for personal protection against airborne viruses and allergens with a triple mode of action.

• At a single Canadian study site, the trial enrolled 37 patients.

• Read Next: Why Are Altamira Therapeutics Shares Gaining Today?

• Under Bentrio treatment, the mean Total Nasal Symptom Score (TNSS) was 4.1 points vs. 5.2 points under no treatment.

• The changes in TNSS started to separate at the 40-minute time point and, on average, reached 1.5 to 2 points from the mid-point to the end of the exposure.

• The protective effect was observed with a single or double puff per nostril with no meaningful difference between the two treatment approaches.

• Regarding safety, there were only a few adverse events, mostly mild, and more than 85% of study participants rated the tolerability of Bentrio as "good" or "very good."

• Price Action: CYTO shares are up 9.39% at $0.94 during the market session on the last check Friday.

See more from Benzinga

• Why TherapeuticsMD Shares Are Trading Higher Today

• Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.